文献速递淋巴瘤

Cirmtuzumab阻断Wnt5a/ROR1刺激的NF-κB抑制慢性淋巴细胞白血病自分泌STAT3活化

Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2019-08-13

本研究探讨Wnt5a/ROR1信号在慢性淋巴细胞白血病(CLL)中激活NF-κB并诱导自分泌IL-6进而活化STAT3的机制。体外共培养和患者样本显示,cirmtuzumab可阻断Wnt5a诱导的NF-κB活化及下游STAT3磷酸化。

要点

  • Wnt5a通过ROR1激活CLL细胞NF-κB,诱导IL-6等因子分泌。
  • 分泌的IL-6以自分泌方式在30分钟内诱导CLL细胞pSTAT3。
  • Cirmtuzumab可抑制CLL患者白血病细胞的NF-κB和STAT3活化。

核心结论

  • Wnt5a/ROR1依赖的信号通路促进CLL细胞NF-κB活化,进而通过自分泌IL-6诱导pSTAT3。
  • Cirmtuzumab能抑制CLL患者白血病细胞的NF-κB和STAT3活化。

研究设计与样本

  • 体外共培养护士样细胞(NLCs)与CLL细胞,并使用抗Wnt5a抗体或抗ROR1单抗cirmtuzumab干预。
  • 对接受cirmtuzumab治疗的患者,检测治疗前后CLL细胞及血浆样本。

主要发现

  • NLCs与CLL细胞共培养诱导白血病细胞STAT3磷酸化(pSTAT3),可被抗Wnt5a抗体或cirmtuzumab阻断。
  • Wnt5a可在30分钟内诱导NF-κB活化,但诱导pSTAT3需超过3小时。
  • CLL细胞培养24小时,Wnt5a诱导IL-6、IL-8、CCL2、CCL3、CCL4和CXCL1表达,这些因子可在30分钟内诱导未刺激CLL细胞的pSTAT3。
  • Wnt5a诱导CLL细胞表达NF-κB靶基因(包括IL-6),该效应可被cirmtuzumab或NF-κB抑制剂阻断。
  • 接受cirmtuzumab治疗的患者样本中,CLL细胞磷酸化p65水平降低、NF-κB和STAT3靶基因表达减少,血浆IL-6水平降低。

临床怎么用

  • cirmtuzumab可能通过阻断Wnt5a/ROR1信号抑制CLL细胞的NF-κB和STAT3活化。
  • 监测NF-κB和STAT3靶基因及血浆IL-6水平或可反映cirmtuzumab的生物学效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coculture of nurse-like cells (NLCs) with chronic lymphocytic leukemia (CLL) cells induced leukemia cell phosphorylation of STAT3 (pSTAT3), which could be blocked by anti-Wnt5a antibodies or the anti-ROR1 monoclonal antibody, cirmtuzumab. Time-course studies revealed Wnt5a could induce activation of NF-κB within 30 minutes, but required more than 3 hours to induce pSTAT3. Culture of isolated CLL cells for 24 hours revealed Wnt5a-induced expression of interleukin 6 (IL-6), IL-8, CCL2, CCL3, CCL4, and CXCL1, which in turn could induce pSTAT3 in unstimulated CLL cells within 30 minutes. We found that Wnt5a could induce CLL cell expression of NF-κB target genes, including IL-6, and that this effect could be blocked by cirmtuzumab or drugs that inhibit NF-κB. Examination of CLL cells and plasma collected from patients treated with cirmtuzumab revealed reduced levels of phosphorylated p65 and diminished expression of NF-κB and STAT3 target genes in CLL cells, as well as lower plasma levels of IL-6, in the samples after therapy. Collectively, these studies indicate that Wnt5a/ROR1-dependent signaling contributes to CLL cell activation of NF-κB, which in turn causes autocrine IL-6-induced activation of pSTAT3. As such, this study demonstrates that cirmtuzumab can inhibit leukemia cell activation of both NF-κB and STAT3 in patients with CLL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chen Y, Chen L, Yu J, et al. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019. PMID: 31409670. doi:10.1182/blood.2019001366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。